Cargando…

Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) guidelines recommend reserving triple therapy of inhaled corticosteroid (ICS), long-acting β(2)-agonist (LABA) and long-acting muscarinic antagonist (LAMA) for patients with exacerbations despite dual therapy. However, many patients receive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vogelmeier, Claus F., Worth, Heinrich, Buhl, Roland, Criée, Carl-Peter, Gückel, Eva, Kardos, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059416/ https://www.ncbi.nlm.nih.gov/pubmed/35501806 http://dx.doi.org/10.1186/s12931-022-02037-2

Ejemplares similares

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
por: Buhl, Roland, et al.
Publicado: (2018)

The Prospective Non-Interventional DACCORD Study in the National COPD Registry in Germany: design and methods
por: Kardos, Peter, et al.
Publicado: (2015)

A year in the life of German patients with COPD: the DACCORD observational study
por: Buhl, Roland, et al.
Publicado: (2016)

“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD
por: Vogelmeier, Claus, et al.
Publicado: (2017)

COPD Assessment Test Changes from Baseline Correlate with COPD Exacerbations: A Longitudinal Analysis of the DACCORD Observational Study
por: Kardos, Peter, et al.
Publicado: (2020)

In ‘real world’ patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations
por: Worth, Heinrich, et al.
Publicado: (2023)

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
por: Voorham, Jaco, et al.
Publicado: (2019)

Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany
por: Worth, Heinrich, et al.
Publicado: (2021)

Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety
por: Suissa, Samy, et al.
Publicado: (2022)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Dual Bronchodilator in the Era of Triple Therapy
por: Papaioannou, Andriana I, et al.
Publicado: (2020)

Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD
por: Kardos, Peter, et al.
Publicado: (2016)

Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations
por: Glaab, Thomas, et al.
Publicado: (2010)

EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
por: Buhl, Roland, et al.
Publicado: (2023)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment
por: Spielmanns, Marc, et al.
Publicado: (2022)

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
por: Vogelmeier, Claus, et al.
Publicado: (2010)

Beyond Dual Bronchodilation – Triple Therapy, When and Why
por: Cazzola, Mario, et al.
Publicado: (2022)

Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany
por: Glaab, Thomas, et al.
Publicado: (2012)

Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial
por: Vogelmeier, Claus F., et al.
Publicado: (2020)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial
por: Bjermer, Leif, et al.
Publicado: (2021)

DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA
por: Kardos, Peter, et al.
Publicado: (2018)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Correction to: DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study
por: Voorham, Jaco, et al.
Publicado: (2020)

Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement
por: Vogelmeier, Claus F, et al.
Publicado: (2021)

Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review
por: Price, David, et al.
Publicado: (2016)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study
por: Juvelekian, Georges, et al.
Publicado: (2015)

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid
por: Miravitlles, Marc, et al.
Publicado: (2022)

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology
por: D’Urzo, Anthony D, et al.
Publicado: (2018)

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
por: Cazzola, Mario, et al.
Publicado: (2019)

Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany – The TriOptimize Study
por: Gessner, Christian, et al.
Publicado: (2022)

Impact of bronchodilator therapy on exercise tolerance in COPD
por: Aguilaniu, B
Publicado: (2010)

The role of bronchodilator treatment in the prevention of exacerbations of COPD
por: Wedzicha, Jadwiga A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8t4bcifs4r9tgtj4k932dam0cl